Why Vera Therapeutics Stock Soared by 22% This Week
Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the company's share price rose by 22%. The appointment of a pair of new executives was encouraging for investors, as was a researcher's new and bullish take on the stock.
On Monday, Vera announced that it has appointed a new chief medical officer and chief development officer. Both appointments were effective immediately.
The incoming chief medical officer is Robert Brenner, who replaces the departing Celia Lin in the position. A nephrologist, Brenner previously served in the same job at several biotechs, including Orionis Biosciences, and was the senior vice president of medical affairs at AMAG Pharmaceuticals. He also served a nearly nine-year stretch as an executive director at big healthcare company .
Source Fool.com
Amgen Inc. Aktie
Uneingeschränkte Unterstützung für Amgen Inc., ausschließlich Buy-Einschätzungen.
Ein Kursziel von 304 € für Amgen Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 289.1 €.
